CNS Healthcare

CNS Healthcare

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

CNS Healthcare is a private, revenue-generating clinical research site network and services company. It provides clinical trial execution services for pharmaceutical sponsors and CROs, primarily in neuroscience (e.g., Alzheimer's, mental health, addiction) but also across a broad range of therapeutic areas. With a seasoned team of board-certified investigators and a multi-site operational footprint, the company positions itself as a patient-centric partner in late-stage clinical development, having contributed to the FDA approval of over 100 treatments.

NeurosciencePsychiatryNeurologyMetabolic DisordersImmunologyPainAddiction Medicine

Technology Platform

Integrated clinical trial execution infrastructure including a network of physical research clinics, a mobile clinic unit for decentralized trials, and operational systems for patient recruitment, screening, protocol administration, and data collection. Leverages telemedicine and standard clinical trial software (EDC, CTMS).

Funding History

2
Total raised:$65M
Series B$45M
Series A$20M

Opportunities

The growing demand for specialized, high-enrolling clinical trial sites in complex therapeutic areas like neuroscience presents a major opportunity.
The industry shift towards decentralized and hybrid trial models also allows CNS to leverage its mobile clinic and telemedicine experience to access broader patient populations and win more sponsor contracts.

Risk Factors

Revenue is entirely dependent on securing contracts from pharmaceutical sponsors and CROs, creating client concentration risk.
Operational risks include patient recruitment delays, protocol compliance issues, and potential adverse events, any of which could damage reputation and lead to financial penalties.

Competitive Landscape

CNS Healthcare competes in a fragmented market with other private clinical research sites, large site networks (e.g., CenExel, Science 37's site network), and academic medical centers. Its differentiation lies in its deep neuroscience/psychiatry investigator expertise, long operational history (since 1996), and a broad therapeutic reach beyond its core focus.